

Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia

Submission date 19/05/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/05/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 11/08/2015	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Davis Dutka

Contact details

University of Cambridge
Addenbrookes Hospital
Hills Road
Cambridge
United Kingdom
CB2 2QQ

Additional identifiers

Protocol serial number

6562

Study information

Scientific Title

Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia

Acronym

GLP-1 and left ventricular function during ischaemia

Study objectives

The hypothesis is that infusion of glucagon-like peptide-1 will protect the heart from ischaemia and improve left ventricular (LV) function during dobutamine stress echocardiography in patients with coronary artery disease

Ethics approval required

Old ethics approval format

Ethics approval(s)

MREC approved, ref: 08/H0304/68

Study design

Single-centre non-randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

Interventions

In the active DSE, patients will receive an infusion of GLP-1 intravenously at 1.2 pmol/kg/min starting 30 minutes prior to the DSE and continuing for 30 minutes into recovery. In the control scan there will be no infusion.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Glucagon-like peptide-1

Primary outcome(s)

Global LV function at peak stress

Key secondary outcome(s)

1. Global LV function at 30 minutes recovery
2. Regional wall LV function at 30 minutes recovery
3. Regional wall LV function at peak stress

Completion date

30/07/2010

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

17/06/2009

Date of final enrolment

30/07/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

University of Cambridge

Cambridge

United Kingdom

CB2 2QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust (UK)

ROR

https://ror.org/04v54gj93

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2012		Yes	No
Results article	results	08/08/2015		Yes	No